Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Inflammation is a natural immune mechanism which chiefly activated to clear dead cells and eliminate the cause of injury. But in some cases, body inappropriately triggers the inflammation to fight back with own cells which may leads to autoimmune diseases such as asthma, COPD etc. Increase in the consumption of anti-inflammatory drugs owing to the appearance of target based anti-inflammatory biologics which are effective with less side effects as compared to conventional drugs. The anti-inflammatory therapeutics is a drug that facilitates acute and chronic pain as well as inflammation (redness, swelling and pain).
The North America anti-inflammatory therapeutics market is witnessing tremendous growth during the forecast period of 2021 to 2027. The anti-inflammatory drugs are used for treatment of asthma and arthritis. The major factors such as increasing prevalence of chronic obstructive pulmonary diseases is propelling the growth of North America anti-inflammatory therapeutics market. Rising new research advancements in anti-inflammatory biologics is boosting the growth of North America anti-inflammatory therapeutics market. Increasing awareness of anti-inflammatory therapeutics and attractive government initiatives are refuelling the growth of North America anti-inflammatory therapeutics market. However, patent expirations of blockbuster drugs is hindering the growth of North America anti-inflammatory therapeutics market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the anti-inflammatory therapeutics market. In addition, complete analysis of changes on anti-inflammatory therapeutics organizations expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on North America economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The COVID-19 has almost affected every market is healthcare industries positively or negatively. Owing to inflammation caused by COVID-19 virus which causes severe pneumonia the anti-inflammatory therapeutics market is witnessing rapid growth. The cytokine rage is chief cause of death in COVID-19 affected patients. Some of the consequences of severe inflammation and cytokine storm comprised of the acute respiratory distress syndrome, acute lung injury and multiple organ dysfunction syndrome which leads to research and development of anti-inflammatory drugs for treatment of the inflammation caused by the COVID-19. Thus, such factors have impacted positively on the growth of anti-inflammatory therapeutics market during the COVID-19 pandemics.
The North America anti-inflammatory therapeutics market is bifurcated into drug class, indication, end user and country.
Drug class such as anti-inflammatory biologics, non-steroidal anti-inflammatory drugs, corticosteroids, immune-selective anti-inflammatory derivative and other are comprised in the North America anti-inflammatory therapeutics market. In which non-steroidal anti-inflammatory drugs is also contributing in the growth of North America anti-inflammatory therapeutics market. The rising use of OTC non-steroidal anti-inflammatory drugs are propelling the growth of North America anti-inflammatory therapeutics market. The growing geriatric populations is also refuelling growth North America anti-inflammatory therapeutics market.
Indication such as arthritis, chronic obstructive pulmonary diseases, multiple sclerosis, inflammatory bowel diseases, asthma, tendonitis and other are comprised in North America anti-inflammatory therapeutics market. In which chronic obstructive pulmonary diseases is also contributing in the growth of North America anti-inflammatory therapeutics market. The COPD is a group of lung diseases that block airflow and make it difficult to breathe. The rising number of early smokers is boosting the growth of North America anti-inflammatory therapeutics market. The growing incidences of lung disorders is also boosting growth of North America anti-inflammatory therapeutics market.
End user such as hospital pharmacies, online pharmacies and retail pharmacies are comprised in the North America anti-inflammatory therapeutics market. In which online pharmacies is also contributing in the growth of North America anti-inflammatory therapeutics market. The rising use of internet is propelling growth of North America anti-inflammatory therapeutics market. The rising surge in technology adoption is also boosting growth of North America anti-inflammatory therapeutics market. Rising offerings by online pharmacies is driving growth of North America anti-inflammatory therapeutics market.
The North America anti-inflammatory therapeutics market is studied for key countries such United States, Mexico and Canada. In which United States is anticipated to dominate the market in 2020. The rising economic development in healthcare industry is propelling growth of North America anti-inflammatory therapeutics market. The growing incidences of chronic obstructive pulmonary diseases is boosting growth of North America anti-inflammatory therapeutics market. The rising prevalence of arthritis is also driving growth of North America anti-inflammatory therapeutics market.
The major key players operating in the market are Amgen Inc, Astrazeneca Plc., Eli Lily And Company., Hoffmann-La Roche Ag, Glaxosmithkline Plc, Johnson & Johnson, Merck & Co., Inc., Novartis Ag and Pfizer Inc among others.
Jun 2020: FDA approved Novartis Ilaris which contains canakinumab for new indication to treat adult-onset still’s disease (AOSD).
March 2020: GSK’s consumer healthcare launched the biggest innovation in the U.S. as Over the counter oral pain relief category under the brand name of Advil dual action which comprised of the acetaminophen and ibuprofen.
The study comprised of the anti-inflammatory therapeutics market. In which study analysed the various segment of the market such as drug class, indication, end user and country. The study also comprised of dominating segment of the market. The drug class segments is dominated by anti-inflammatory biologics. Likewise, indication segment is dominated by arthritis, end user segment is dominated by hospital pharmacies and country segment is dominated by the United States. The study also covers the impact of COVID-19 on the anti-inflammatory therapeutics market and concludes that the COVID-19 has almost affected every market is healthcare industries positively or negatively. Owing to inflammation caused by COVID-19 virus which causes severe pneumonia the anti-inflammatory therapeutics market is witnessing rapid growth. The cytokine rage is chief cause of death in COVID-19 affected patients. Some of the consequences of severe inflammation and cytokine storm comprised of the acute respiratory distress syndrome, acute lung injury and multiple organ dysfunction syndrome which leads to research and development of anti-inflammatory drugs for treatment of the inflammation caused by the COVID-19. Thus, such factors have impacted positively on the growth of anti-inflammatory therapeutics market during the COVID-19 pandemics. The study also imparts the major key players operating in the market.
Why to buy this report
